May 2015
Table of Contents

Funding Opportunities

NCI Exploratory / Developmental Research Grant Program (NCI Omnibus R21)


Limited Competition: Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54


Peer Reviewed Cancer Research Program Translational Team Science Award

View a full list of current funding opportunities. 

Highlighted positions related to cancer for which VCU is currently hiring. View the full list. 

Associate Director, Cancer Prevention & Control (F39570)  

Shared Resource Spotlight
Flow Cytometry

The Flow Cytometry Shared Resource Core is please to now offer support for protein interaction studies utilizing a BiaCore T100 Surface Plasmon Resonance (SPR) instrument as well as Microplate luminescence capability with our Perkin Elmer TopCount System.

The Flow Cytometry core also

provides a wide range of services related to cell sorting and analysis including everything from routine fluorescence analysis to interactive custom design of innovative analysis and sorting protocols that address the specific needs of individual investigators.

Leaders' UpdateUpdate

A message from Associate Director Rick Moran

The answers emerging from The Cancer Genome Atlas (TCGA) project have taught us that almost every cancer has multiple genetic changes as well as dozens of other random mutations that become fixed in the genome because of the loss of function of the mechanisms needed to proofread the DNA. There is also strong evidence that there is genomic heterogeneity in tumors.


Although the cancer cell has found a multitude of mutations that allow it to escape control, the functions of the proteins involved all cluster in a small number of pathways. Hence, we now know exactly what is wrong in almost all of the tumor types, and we know how to aim our therapies. What we need now is more research into how these pathways function and how the multitude of new agents aimed against specifically those pathways, now called "targeted chemotherapeutic drugs," should be used.


To accomplish these goals, Massey has assembled in the Developmental Therapeutics program a moderately large group of investigators with expertise covering the gamut of therapeutic research. The key to the advances now needed is communication between basic science researchers and clinical scientists. These collaborations are further facilitated by the early phase working groups and Massey's Clinical Trials Office through the process of translation.

Research HighlightsHighlights
Failure to expand ACA Medicaid coverage would widen disparities in screening uninsured and low-income women for breast and cervical cancer

Cancer Prevention and Control
Massey researchers recently conducted a study led by Lindsay Sabik that found low-income and uninsured women in states that are not expanding their Affordable Care Act Medicaid coverage are less likely to receive breast and cervical cancer screenings compared to states that are implementing expansions. 

Massey researcher leads team to improve data reporting of meningioma treatment outcomes

Radiation Biology and Oncology

A new study led by Massey physician-researcher Leland Rogers found that clinical trials to treat the most common primary brain tumor, meningioma, lack uniform guidelines for how physicians should determine whether treatment is effective at shrinking the tumor.


Center News Center1
Massey becomes the only medical provider in Richmond to offer Interleukin-2 therapy

Giao Phan
Developmental Therapeutics

Massey is now offering FDA-approved Interleukin-2 (IL-2) therapy for metastatic melanoma and metastatic renal cell carcinoma, making Massey the only medical provider in the Richmond area to offer this service. IL-2 treatment is a type of immunotherapy that stimulates the body's immune system to recognize and kill tumor cells. At Massey, IL-2 is provided by Giao Phan.


Member Showcase MemberShowcase
Cancer Molecular Genetics welcomes Jennifer Koblinski as research member

Cancer Molecular Genetics
Massey welcomes Jennifer Koblinski as a research member in the Cancer Molecular Genetics program.  Koblinski joined the VCU Department of Pathology as an assistant professor in 2013.

Koblinski's primary research interest focuses on the mechanisms that facilitate breast cancer metastasis to the brain. In the last five years, Koblinski has been awarded more than $40 million in grants and contracts to support this research, with findings published in peer-reviewed journals and by peer- and non-peer-reviewed editorials, reviews and book chapters.  

Researcher Recognition Recognition
Massey researcher receives NIH grant to study unknown factors controlling adaptive low-oxygen cell response that aids in cancer growth

Cancer Cell Signaling
Massey researcher Keith Baker received a $219,030 Exploratory/Developmental Research (R21) grant from the National Institutes of Health to identify the components that help cells adapt and survive in low-oxygen conditions that occur in novel cell signaling pathways. This study will be the first of its kind that will specifically assess HIF-independent low-oxygen responses in an intact organism.

EventsUpcoming Events

Cancer Research Seminars
Join us for a Massey summer tradition!

Join Massey supporters, volunteers and staff to dance the night away at the Massey Alliance's 13th Annual Moonlight Magic. One general admission ticket ($45) gives you access to live music by the Remnants, delicious food options, two drink tickets to enjoy any of the James RIver Cellars wines, specialty and frozen beverages and enticing silent and live auctions.

For a full listing of events, 
Share with us your research, awards and accomplishments!
Submit your news to Stevi Antosh at or (804) 628-4578.
 Connect with us!
Join Massey's online communities.
Like us on Facebook
Follow us on Twitter
View our videos on YouTube